Original paper
polyethylene glycol conjugated insulin-like growth factor binding protein-1 (IGFBP-1) inhibits growth of breast cancer in athymic mice

https://doi.org/10.1016/S0959-8049(97)00071-3Get rights and content

Abstract

Insulin-like growth factor (IGF) binding protein-1 (BP-1) inhibits IGF-mediated proliferation of some breast cancer cell lines in vitro. Here we examined whether recombinant human wild-type IGFBP-1 (WT-BP-1) and IGFBP-1 conjugated with polyethylene glycol (PEG-BP-1) could inhibit breast cancer growth. Three breast cancer cell lines were used: MCF-7, MDA-MB-231 and MDA-MB-435A (ascites model). The cells were grown in agar with or without the BP-1 conjugates to investigate their effect on colony formation. Both WT-BP-1 and PEG-BP-1 inhibited anchorage-independent growth (AIG) of MCF-7 and MDA-MB-435A cells. AIG of MDA-MB-231 cells was not inhibited by PEG-BP-1, whereas WT-BP-1 significantly stimulated colony number. We also tested both forms of BP-1 in xenograft tumour models. Two solid breast tumour models were studied using MCF-7 and MDA-MB-231 cell lines, and one ascites model using the MDA-MB-435A cell line. PEG-BP-1 inhibited malignant ascites formation in the MDA-MB-435A model. Conversely, PEG-BP-1 did not significandy inhibit MCF-7 xenograft growth. However, the MDA-MB-231 tumour growth curves were significantly different by a constant amount, suggesting that PEG-BP-1 treatment inhibited early tumour growth of this cell line. In contrast, WT-BP-1 was ineffective in the MDA-MB-231 tumours. These data show that anti-IGF strategies can be used to inhibit breast cancer cell growth. Since PEG-BP-1 inhibited the in vivo, but not in vitro, growth of MDA-MB-231, we speculate that PEG-BP-1 may block host IGF functions required for optimal tumorigenesis. Because PEG-BP-1 has a prolonged serum half-life compared to WT-BP-1, we conclude that improvements in BP-1 pharmacological properties enhanced its antitumour effects in vivo.

References (30)

  • J Nakao-Hayashi et al.

    Stimulatory effects of insulin and insulin-like growth factor on migration and tube formation by vascular endothelial cells

    Atherosclerosis

    (1992)
  • MB Grant et al.

    Insulin-like growth factor I as an angiogenic agent

    Ann NY Acad Sci

    (1993)
  • C Sell et al.

    Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts

    Mol Cell Biol

    (1994)
  • M Resnicoff et al.

    The insulin-like growth factor I receptor protects tumor cells from apoptosis in vivo

    Cancer Res

    (1995)
  • C Singer et al.

    Malignant breast epithelium selects for insulin-like growth factor II expression in breast stroma: evidence for paracrine function

    Cancer Res

    (1995)
  • Cited by (52)

    • Airway smooth muscle cells are insensitive to the anti-proliferative effects of corticosteroids: The novel role of insulin growth factor binding Protein-1 in asthma

      2019, Immunobiology
      Citation Excerpt :

      Several studies investigated the role of IGFBP1 in modulating cell growth. For instance, IGFBP-1 decreases the growth of breast cancer cells in response to estrogen and serum (Van den Berg et al., 1997) and the thymidine uptake in rat aortic smooth muscle cells (Motani et al., 1995). Evidence suggests that IGFBP-1 downregulates the expression of key proteins associated with cell growth such as ERK and AKT in fibroblasts (Prokop et al., 2013).

    • Aiming for the Insulin-like Growth Factor-1 system in breast cancer therapeutics

      2018, Cancer Treatment Reviews
      Citation Excerpt :

      In addition, some IGFBPs may exert their anti-tumor activities via an IGF-1-independent manner [39,40], however may also prolong the IGF-1 induced signal transduction via partial ligand release. It has been previously addressed that both exogenous and endogenous IGFBP1 may suppress the IGF-1 induced motility and growth of breast tumors in vitro and in athymic mice [41–44]. In contrast to IGFBP1, IGFBP2 is considered to have oncogenic activities in breast and other malignancies, although results remain conflicting [45].

    • Indole-3-Carbinol disrupts Estrogen Receptor-alpha dependent expression of Insulin-like Growth Factor-1 Receptor and Insulin Receptor Substrate-1 and proliferation of human breast cancer cells

      2012, Molecular and Cellular Endocrinology
      Citation Excerpt :

      Elucidation of the IGF1 receptor activated signaling cascade and its role in controlling proliferation of breast cancer cells has influenced the development of several therapeutic strategies that target this pathway. One approach has been to disrupt IGF1 binding to IGF1R, either by employing neutralizing monoclonal antibodies directed against IGF1, or by increasing levels of IGF binding proteins (IGFBP), which naturally bind and sequester IGF1 (Goya et al., 2004; Van den Berg et al., 1997). In a complementary manner, monoclonal antibodies can be directed toward IGF1R to induce receptor-mediated endocytosis, followed by proteolytic degradation (Lee et al., 2003; Sachdev et al., 2003; Wang et al., 2005).

    • Role of insulin-like growth factor-1R system in colorectal carcinogenesis

      2008, Critical Reviews in Oncology/Hematology
      Citation Excerpt :

      Also, co-injection of cells expressing 486/STOP with wild-type tumor cells inhibited the growth of wild-type tumor cells secondary to a bystander effect [50]. IGF binding proteins (IGFBP-1 and IGFBP-3) are also being investigated as possible anticancer agents [51,52]. The IGF system plays an important role in tumorigenesis and has been shown to be an absolute requirement for the establishment and maintenance of the transformed phenotype [53].

    View all citing articles on Scopus
    View full text